News & Events about Edwards Lifesciences Corp.
UBS Group began coverage on shares of Edwards Lifesciences (NYSE:EW Get Rating) in a report published on Tuesday , The Fly reports. The firm issued a neutral rating and a $84.00 price objective on the medical research companys stock. Several other research firms have also commented on...
Teacher Retirement System of Texas lowered its stake in shares of Edwards Lifesciences Co. (NYSE:EW Get Rating) by 34.1% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 116,217 shares of the medical research ...
Edwards Lifesciences Co. (NYSE:EW Get Rating) CEO Michael A. Mussallem sold 19,875 shares of the firms stock in a transaction dated Friday, January 13th. The stock was sold at an average price of $78.09, for a total value of $1,552,038.75. Following the completion of the sale, the ...